Drugs / anti-anb3 integrin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00052403 | Feb 2002 → ? | cancer of unknown primary site | Barbara Ann Karmanos Cancer Institute | Withdrawn | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | anti-anb3 integrin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00052403 ↗ |
| Modality | Monoclonal antibody | “monoclonal antibody anti-anb3 integrin” NCT00052403 ↗ |
| Route | Intravenous | “IV over 30 minutes” NCT00052403 ↗ |